144 related articles for article (PubMed ID: 17359286)
21. Assessing the safety of autologous stem cell transplant pathway via ambulatory care for patients with multiple myeloma.
Yip HM; Yong K; De-Silva D; Rabin N
Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):160-162. PubMed ID: 32192978
[TBL] [Abstract][Full Text] [Related]
22. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC;
Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586
[TBL] [Abstract][Full Text] [Related]
23. Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities.
Guman T; Sykora J
Bratisl Lek Listy; 2024; 125(1):9-11. PubMed ID: 38041839
[TBL] [Abstract][Full Text] [Related]
24. Safety and survival outcomes for bloodless transplantation in patients with myeloma.
Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR; Graiser M; Heffner LT; Lonial S; Nooka AK
Cancer; 2019 Jan; 125(2):185-193. PubMed ID: 30480777
[TBL] [Abstract][Full Text] [Related]
25. [High dose therapy with autologous stem cell transplantation in patients with Hodgkin's lymphoma: long-term follow-up in patients treated in one center].
Trnĕný M; Vacková B; Pytlík R; Cieslar P; Válková V; Gasová Z; Kobylka P; Trnková M; Krejcová H; Klener P
Cas Lek Cesk; 2006; 145(1):19-24. PubMed ID: 16468237
[TBL] [Abstract][Full Text] [Related]
26. All transplantation-eligible patients with myeloma should receive ASCT in first response.
Moreau P; Attal M
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):250-4. PubMed ID: 25696863
[TBL] [Abstract][Full Text] [Related]
27. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
[TBL] [Abstract][Full Text] [Related]
28. Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis.
Lin CM; Chang LC; Shau WY; Chen CL; Yao CY; Tien FM
BMC Cancer; 2023 May; 23(1):446. PubMed ID: 37193978
[TBL] [Abstract][Full Text] [Related]
29. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
30. The role of tandem stem cell transplantation for multiple myeloma patients.
Martino M; Recchia AG; Fedele R; Neri S; Vincelli ID; Moscato T; Gentile M; Morabito F
Expert Opin Biol Ther; 2016; 16(4):515-34. PubMed ID: 26698133
[TBL] [Abstract][Full Text] [Related]
31. IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy.
Pisani F; Petrucci MT; Giannarelli D; Bongarzoni V; Montanaro M; De Stefano V; La Verde G; Gentilini F; Levi A; Za T; Moscetti A; Annino L; Petti MC;
J Exp Clin Cancer Res; 2012 Mar; 31(1):17. PubMed ID: 22381082
[TBL] [Abstract][Full Text] [Related]
32. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
33. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M
J Clin Oncol; 2009 Oct; 27(30):5001-7. PubMed ID: 19720903
[TBL] [Abstract][Full Text] [Related]
34. [Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].
Hayashi T; Yasui H; Kawakami K; Ikeda H; Takahashi F; Kobayashi T; Nishimura S; Ishida T; Imai K; Shinomura Y
Rinsho Ketsueki; 2011 Mar; 52(3):136-41. PubMed ID: 21471701
[TBL] [Abstract][Full Text] [Related]
35. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies.
Naumann-Winter F; Greb A; Borchmann P; Bohlius J; Engert A; Schnell R
Cochrane Database Syst Rev; 2012 Oct; 10():CD004626. PubMed ID: 23076906
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
Gay F; Magarotto V; Crippa C; Pescosta N; Guglielmelli T; Cavallo F; Pezzatti S; Ferrari S; Liberati AM; Oliva S; Patriarca F; Offidani M; Omedé P; Montefusco V; Petrucci MT; Giuliani N; Passera R; Pietrantuono G; Boccadoro M; Corradini P; Palumbo A
Blood; 2013 Aug; 122(8):1376-83. PubMed ID: 23775712
[TBL] [Abstract][Full Text] [Related]
37. Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction.
Gao W; Geng C; Zhang L; Li Y; Chen W; Wang C
Hematology; 2013 Nov; 18(6):341-7. PubMed ID: 23510553
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.
Eom KS; Min CK; Lee S; Kim YJ; Kim SY; Kim HJ; Lee JW; Min WS; Kim CC
Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727
[TBL] [Abstract][Full Text] [Related]
39. The role of autologous stem cell transplantation in the management of multiple myeloma.
Fermand JP; Brechignac S
Pathol Biol (Paris); 1999 Feb; 47(2):199-202. PubMed ID: 10192889
[TBL] [Abstract][Full Text] [Related]
40. [Single vs double stem cell transplantation for the treatment of multiple myeloma].
Tamura H
Nihon Rinsho; 2015 Jan; 73(1):85-9. PubMed ID: 25626310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
